The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place.
Government is expanding prescription coverage for long-acting muscarinic antagonist (LAMAs) inhalers, used in the treatment of Chronic Obstructive Pulmonary Disease. The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place. This will ensure NLPDP beneficiaries have timely access to these inhalers for the treatment of their COPD.
Police looking for wanted man seen in Corner Brook and Bay St. George
Deputy Premier says government's role is to pave the way for businesses to prosper
Premier Wakeham to host New England Governors and Eastern Canadian Premiers on Monday
Western Regional Waste Management recommends taping the ends of batteries to be recycled
Gingerbread House at Valley Mall has delivered over 107,000 gifts for children since starting in 1982
